Medpace Holdings Inc
MEDP: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $!> | LOCK|Sw#& | LOCK|t^Mzv> |
Medpace Earnings: Solid Growth Amid Fewer Cancellations; Replenishing Backlog Will Be Key
Medpace's third-quarter revenue increased nearly 24% from the prior-year period. Management raised its 2025 revenue and adjusted EBITDA guidance by 1.4% and 3.8% at the midpoint, respectively. Net new business awards totaled $789 million, and Medpace reported a net book/bill ratio of 1.20.
